Compare NXPL & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NXPL | RVPH |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | 180 | 14 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0M | 10.0M |
| IPO Year | N/A | N/A |
| Metric | NXPL | RVPH |
|---|---|---|
| Price | $0.45 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $66.67 |
| AVG Volume (30 Days) | 432.0K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.17 |
| 52 Week High | $1.11 | $3.11 |
| Indicator | NXPL | RVPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.41 | 43.85 |
| Support Level | $0.41 | $0.32 |
| Resistance Level | $0.69 | $0.86 |
| Average True Range (ATR) | 0.07 | 0.19 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 38.30 | 6.12 |
NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.